KF 0210
Alternative Names: KF-0210; KF-0210-0Latest Information Update: 28 Feb 2024
At a glance
- Originator Keythera Pharmaceuticals (Australia)
- Class Antineoplastics
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Australia (PO, Tablet)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Monotherapy, Second-line therapy or greater) in Australia (PO, Tablet)
- 14 Apr 2023 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical study in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)